Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia. First-in-class Bruton’s tyrosine kinase (BT ...

SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter ...

This review highlights the critical role of ubiquitin-specific proteases (USPs) in regulating programmed cell death (PCD) in breast cancer (BC). As the most prevalent malignant tumor among women, BC ...

The discovery centres on the proteasome – a tiny structure that is found in every cell of the body. Its main role is to chop ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Native gel electrophoresis revealed a higher proportion of doubly-capped 26S proteasome (19S-20S-19S) in the cortex than in the liver or kidney. To investigate the interplay between proteasome ...

HTC Desire 19s is powered by the Mediatek MT6762 Helio P22 Octa-core 2.0 GHz Cortex-A53 processor. The smartphone comes with a 6.2 inches IPS LCD capacitive touchscreen and 720 x 1520 pixels ...

The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have ...

In the EU, Japan and the US, Sarclisa plus Pd is approved for individuals with relapsed or refractory MM who have undergone two or more previous therapies, including lenalidomide and a proteasome ...

Department of Pediatrics, Pediatric Intensive Care Unit, Shengjing Hospital of China Medical University, Shenyang (N.Y., Y.-P.L., R.W., Y.-H.Y., T.Z., X.-R.Y., Y.-F.X ...

including lenalidomide and a proteasome inhibitor. Sarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct ...